Search
Selected Filter
Filter Results
Displaying 31–40 of 589 news results
-
May 1, 2026
Foundation NewsThe award recognizes Dr. Pierce’s contributions to inherited retinal disease research, including work that led to the first FDA-approved gene therapy for an inherited disease and leadership of the world’s first in vivo CRISPR genome-editing study in humans.
-
Apr 22, 2026
In the PressFour-year cohort will enroll participants with inherited retinal diseases caused by mutations in the RHO gene. Study is intended to deepen understanding of disease progression and inform future clinical trial design in rhodopsin-associated retinal disease.
-
Apr 21, 2026
Atsena Therapeutics Advances to Pivotal Phase 3 Trial for X-Linked Retinoschisis
Research NewsData monitoring committee recommends proceeding with registration-enabling study for ATSN-201
-
Apr 20, 2026
Foundation NewsThe gathering will be held June 12–13 and will convene global communities impacted by blinding diseases, alongside researchers, clinicians, patient advocates, and industry partners to foster collaboration, innovation, and hope.
-
Apr 16, 2026
MeiraGTx Acquires XLRP Gene Therapy Bota-Vec, Moves Toward Regulatory Filing
Research NewsMeiraGTx has acquired bota-vec, a gene therapy for X-linked retinitis pigmentosa (XLRP), and plans to file for regulatory approval in the U.S., Europe, and Japan, with a potential launch in 2027.
-
Apr 8, 2026
Opus Genetics Secures $155 Million Financing to Accelerate Gene Therapy Pipeline
Research NewsStrategic funding extends cash runway through 2029 and advances multiple inherited retinal disease programs
-
Apr 8, 2026
Illuminating the Future: Highlights from Investing in Cures Summit 2026
Foundation NewsAt ICS 2026 in Boston, leading researchers, clinicians, and industry pioneers shared the latest advances in gene therapy, precision genetic medicine, and gene-agnostic approaches for inherited retinal diseases.
-
Apr 7, 2026
Recording Available: Insights Forum | Thursday, March 26, 2026
Foundation NewsThe Foundation Fighting Blindness is pleased to provide a recording and full transcript of the Insights Forum, our quarterly conference call providing updates to the blinding diseases community. The call took place on March 26, 2026.
-
Mar 26, 2026
VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy
Research NewsVG801 shows sustained vision improvements through 12 months with favorable safety profile
-
Mar 24, 2026
Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
Research NewsPotential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.